Regal Assets Analytics

Call Us: (800) 891-1526

M - F 8AM to 4PM ET

WDLangbein

About Bill Langbein

Before starting SanaCurrents, William (Bill) Langbein spent more than 20 years as a life science business journalist, with stops at California Medicine, In Vivo and Reuters Health. During that time, he wrote on genomic discoveries, the transition of the pharmaceutical companies to rely more on biologics, and the dawn of precision medicine, through which most drug developers came to recognize a one-drug-for-all approach would no longer work. One constant truth he learned is smaller companies deliver the most innovation and highest value to patients and investors. Yet because of the inherent volatility of biopharma and medical devices, small companies typically fly under the radar of investors. The emergence of precision medicine, however, reduces the volatility of small cap companies and increases the potential for strong returns. SanaCurrents was founded to identify the undervalued therapies that would benefit patients and investors the most.

Gritstone, BioXcel Expect to Report Catalysts in July 2020; 2Q SanaCurrents Update

By |2020-07-07T07:48:32-04:00July 6th, 2020|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Updates|

Gritstone Oncology (NASDAQ:GRTS) plans to hold a conference call and [...]

New Magenta Catalyst MGTA-145 After Company Drops MGTA-456 Phase II Trial

By |2020-07-06T10:23:39-04:00June 26th, 2020|Categories: Bill Langbein, SanaCurrents, SanaCurrents Probability Sentiment, SanaCurrents Updates|Tags: |

Shares of Magenta Therapeutics (NASDAQ: MGTA) declined 22% on June [...]

Molecular Templates (MTEM) Probability Sentiment

By |2020-07-06T10:24:03-04:00June 13th, 2020|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Probability Sentiment|

Molecular Templates, Inc. (NASDAQ:MTEM) Probability Sentiment [...]

Selecta Licenses Away Promising Gout Drug; SanaCurrents Suspending Coverage

By |2020-07-06T10:24:12-04:00June 12th, 2020|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents Updates|Tags: , , |

After the market closed on June 11, Selecta Biosciences, Inc. [...]